
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic's stock outlook remains positive due to strong growth in its neuromodulation and diabetes segments, with reported revenue growth in the low double digits driven by the increasing adoption of the MiniMed 780G AID system. The company's forecast for FY25 indicates a projected revenue increase of 4.75-5.00% along with EPS growth of 10-11% year-over-year, signaling robust financial performance independent of foreign exchange fluctuations. Additionally, improvements in non-GAAP gross and operating margins further enhance the financial profile, reflecting operational efficiency and favorable market conditions in key therapeutic areas.
Bears say
Medtronic's outlook appears negative primarily due to anticipated slowing revenue growth, projected to decline to low single digits amidst unsuccessful new product launches and market share losses, particularly in key product categories. Additionally, the company's operating margins are likely to remain flat or deteriorate, contributing to earnings that fall below market consensus. Ongoing risks, including competitive pressures, disappointing sales from new product segments, and adverse foreign currency impacts, further underscore the potential for continued financial challenges, as evidenced by recent sales misses and a decline in Medical Surgical revenues.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares